Ten-year graft survival of deceased-donor kidney transplantation: A single-center experience

Renal Failure

Volumn 32, Issue 4, 2010, Pages 440-447

  Hashiani, Amir Almasi ^a   Rajaeefard, Abdolreza ^a   Hasanzadeh, Jafar ^a   Kakaei, Farzad ^b   Behbahan, Afshin Ghalehgolab ^b   Nikeghbalian, Saman ^c   Salahi, Heshmatollah ^c   Bahador, Ali ^c   Salehipour, Mehdi ^c   Malek Hosseini, Seyed Ali ^c  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Deceased donor; Graft survival rate; Renal transplantation

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOSPORIN A; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS;

ADULT; ARTICLE; CADAVER KIDNEY; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IRAN; KIDNEY ALLOGRAFT REJECTION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME;

ADOLESCENT; ADULT; AGED; CADAVER; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CREATININE; FEMALE; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; INFANT; IRAN; KIDNEY TRANSPLANTATION; LENGTH OF STAY; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; RISK FACTORS; SURVIVAL RATE;

EID: 77952199761     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/08860221003650347     Document Type: Article

References (37)

1. Abbaszadeh S, Nourbala MH, Taheri S, et al. Renal transplantation from deceased donor in Iran. Saudi J Kidney Dis Transpl. 2008;19(4):664-668.
2. Abboud O. Incidence, prevalence and treatment of end stage renal disease in the Middle East. Ethn Dis. 2006;16(Suppl. 2): S2-2-S2-4.
3. Mahdavi-Mazdeh M, Heidari-Rouchi A, Aghighi M, et al. Organ and tissue transplantation in Iran. Saudi J Kidney Dis Transpl. 2008;19(1):127-131.
4. Mahdavi-Mazdeh M, Heidary-Rouchi A, Norozi S, et al. Renal replacement therapy in Iran. Urol J. 2007;4:66-70.
5. Schena FP. Epidemiology of end stage renal disease: International comparisons of renal replacement therapy. Kidney Int. 2000;57:39-45.
6. Hariharan S, Johnson CP, Barbara A, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med. 2000;342:605-612.
7. Cacho DT, Cusi LIP, Pique AA, et al. Elderly donor kidney transplant: Factors involved in graft survival. Transplant Proc. 2005;37:3690-3992.
8. Kriesche HUM, Port FK, Ojo AO, et al. Effect of waiting time on renal transplant outcome. Kidney Int. 2000;58:1311-1317.
9. Shrestha BM, Haylor JL. Factors influencing long term outcome following renal transplantation: A review. J Nepal Med Assoc. 2007;46(167):136-142.
10. Ghods AJ. Renel transplantation in Iran. Nephrol Dial Transplant. 2002;17:222-228.
11. Foster CE, Weng RR, Pharm D, et al. The influence of organ acceptance criteria on long term graft survival: Outcome of a kidney transplant program. Am J Surg. 2008;195:149-152.
12. Tan SY, Chen TP, Lee SH, et al. Cadaveric renal transplantation at university hospital Kuala Lumpur: A preliminary report. Transplant Proc. 2000;32:1811-1812.
13. Cecka JM. The UNOS renal transplant registry. Clin Transplant. 2001;7;1-18.
14. Meier-Kriesche HU, Cibrik OM, Ojo AO, et al. Interaction between donor and recipient age in determining the risk of chronic renal allograft failure. J Am Geriatr Soc. 2002;50:14-17.
15. Denton MD, Singh AK. Recurrent and de novo glomerulonephritis in the renal allograft. Semin Nephrol. 2000;20:164-175.
16. Womer KL, Vella JP, Sayegh MH. Chronic allograft dysfunction: Mechanisms and new approaches to therapy. Semin Nephrol. 2000;20:126-147.
17. Ojo AO, Hanson JA, Wolfe RA, et al. Long-term survival in renal transplant recipients with graft function. Kidney Int. 2000;57:307-313.
18. Takemoto SK, Terasaki PI, Gjertson DW, et al. Twelve years' experience with national sharing of HLA-matched cadaveric kidneys for transplantation. N Engl J Med. 2000;343:1078-1084.
19. Kwon OJ, Ha MK, Kwak JY, et al. The impact of delayed graft functions on graft survival in living donor kidney transplantation. Transplant Proc. 2003;35:92-93.
20. Mange K, Feldman H. Blood pressure and prediction of patient outcome. Kidney Int. 2000;57:2655.
21. Akioka K, Takahara S, Ichikawa S, et al. Factors predicting long-term graft survival after kidney transplantation: Multi center study in Japan. World J Surg. 2005;29:249-256.
22. Meier-Kriesche HU, Arndorfer JA, Kaplan B, et al. The impact of body mass index on renal transplant outcomes: A significant independent risk factor for graft failure and patient death. Transplantation. 2002;73:70-74.
23. Meier-Kriesche HU, Kaplan B. Cyclosporine microemulsion and tacrolimus are associated with decreased chronic allograft failure and improved long-term graft survival as compared with Sandimmune. Am J Transplant. 2002;2:100-104.
24. Port FK, Dykstra DM, Merion RM, Wolfe RA. Trends and results for organ donation and transplantation in the United States 2004. Am J Transplant. 2005;5(4 Pt. 2):843-849.
25. Pugliese O, Quintieri F, Mattucci DA, Venettoni S. Kidney graft survival in Italy and factors influencing it. Prog Transplant. 2005;15(4):385-391.
26. Truan Cacho D, Peri Cusí LI, Agud Piqué A, et al. Elderly donor kidney transplant: Factors involved in graft survival. Transplant Proc. 2005;37:3690-3692.
27. Wu C, Evans I, Joseph R, et al. Comorbid conditions in kidney transplantation: Association with graft and patient survival. J Am Soc Nephrol. 2005;16:3437-3444.
28. Giblin L, O'Kelly P, Little D, et al. A comparison of long-term graft survival rates between the first and second donor kidney transplanted-the effect of a longer cold ischemic time for the second kidney. Am J Transplant. 2005;5:1071.
29. Einollahi B. Iranian experience with the non-related renal transplantation. Saudi J Kidney Dis Transpl. 2004;15(4): 421-428.
30. Meier-Kriesche HU, Li S, Gruessner RW, et al. Immunosuppression: Evolution in practice and trends, 1994-2004. Am J Transplant. 2006;6(5 Pt. 2):1111-1131.
31. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation. 1995;60:225.
32. Shapiro R, Jordan ML, Scantlebury VP, et al. A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/ prednisone/mycophenolate mofetil in renal transplant recipients. Transplantation. 1999;67:411.
33. Ojo AO, Meier-Kriesche HU, Hanson JA, et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation. 2000;69:2405.
34. Ciancio G, Miller J, Gonwa TA. Review of major clinical trials with mycophenolate mofetil in renal transplantation. Transplantation. 2005;80:S191.
35. Remuzzi G, Cravedi P, Costantini M, et al. Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: The MYSS follow-up randomized, controlled clinical trial. J Am Soc Nephrol. 2007;18:1973.
36. Shapiro R, Jordan ML, Scantlebury VP, et al. Reducing the length of stay after kidney transplantation - the intensive outpatient unit. Clin Transplant. 1998;12:482.
37. Lin S-J, Koford JK, Baird BC, et al. The association between length of post-kidney transplant hospitalization and long-term graft and recipient survival. Clin Transplant. 2006;20:245-252.